Edition:
United States

Molecular Medicine SpA (MLMD.MI)

MLMD.MI on Milan Stock Exchange

0.49EUR
18 May 2018
Change (% chg)

€-0.00 (-0.10%)
Prev Close
€0.49
Open
€0.49
Day's High
€0.50
Day's Low
€0.49
Volume
1,782,070
Avg. Vol
4,117,939
52-wk High
€0.60
52-wk Low
€0.40

Chart for

About

Molecular Medicine SpA (MolMed) is an Italy-based company engaged in the medical biotechnology sector. The Company is active in the research, development and clinical validation of therapies for the treatment of cancer. The Company’s activities include identification and development of bio-pharmaceuticals reducing the tumor mass... (more)
No analyst recommendations are available for .

Overall

Beta: 1.08
Market Cap(Mil.): €225.55
Shares Outstanding(Mil.): 456.96
Dividend: --
Yield (%): --

Financials

  MLMD.MI Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -0.02 -- --
ROI: -29.21 -8.07 12.63
ROE: -36.33 -10.87 14.50

BRIEF-Molmed SpA Signs Master Service Agreement With Boston Children's Hospital For Supply Of Lentiviral Vectors

* SIGNS 5 YEAR MASTER SERVICE AGREEMENT WITH BOSTON CHILDREN'S HOSPITAL FOR SUPPLY OF LENTIVIRAL VECTORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 04 2018

BRIEF-Molmed FY Net Loss Shrinks To EUR 8.5 Mln

* REPORTED ON FRIDAY FY TOTAL OPERATING REVENUES EUR 24.0 MLN VS EUR 22.8 MLN YEAR AGO

Mar 12 2018

BRIEF-Molmed: Dompé Exercises Option To Start Zalmoxis In Switzerland, Turkey And Australia

* DOMPÉ EXERCISES OPTION TO ENTER MARKETS IN SWITZERLAND, TURKEY AND AUSTRALIA TO SELL ZALMOXIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 08 2018

BRIEF-Molmed: Italian Medicines Agency Sets Price Of Reimbursement For Zalmoxis

* ITALIAN MEDICINES AGENCY SETS GROSS PRICE OF REIMBURSEMENT FOR ZALMOXIS AT EUR 149,000 PER INFUSION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Dec 13 2017

Earnings vs. Estimates